Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
Letter to the Editor: Finerenone and proteinuria in diabetic kidney disease
Vaia D Raikou, Department of Nephrology, Doctors’ General Clinic, Athens 11257, Greece
Sotiris Gavriil, Department of Weight-Surgery, Doctors’ Hospital, Athens 11257, Greece
Author contributions: Raikou VD and Gavriil S contributed to research plan; Raikou VD contributed to manuscript writing; Gavriil S contributed to approval of written manuscript.
Conflict-of-interest statement: All authors declare that they have no conflict of interest to disclose.
Corresponding author: Vaia D Raikou, PhD, Chief, Department of Nephrology, Doctors’ General Clinic, 26 Kefallinias, Athens 11257, Greece. vraikou@med.uoa.gr
Received: April 7, 2026
Revised: April 27, 2026
Accepted: May 13, 2026
Published online: September 25, 2026
Processing time: 132 Days and 11.2 Hours
Revised: April 27, 2026
Accepted: May 13, 2026
Published online: September 25, 2026
Processing time: 132 Days and 11.2 Hours
Core Tip
Core Tip: Diabetic nephropathy is mainly characterized by proteinuria, which contributes to renal progression and cardiovascular complications. Finerenone, a novel nonsteroidal mineralocorticoid receptor antagonist, can reduce proteinuria with a dependance on initial baseline proteinuria, despite its effect may be disproportional and variant. More factors including genetics or epigenetics may be involved in diabetic kidney pathology, because of which proteinuria persists.